02/09/2015 10:49:53 Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
09/02/20158:00AMPRNUSMylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceeding against Third Copaxone® 40 mg/...
Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceeding against Third Copaxone® 40 mg/mL Dosing Patent on All Claims PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 2, 2015 HERTFORDSHIRE, England and PITTSBURGH, Sept. 2, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today... More...>>
08/28/20158:20AMDJNMylan Holders Approve Perrigo Purchase
Mylan N.V. said Friday that its shareholders have approved its proposed $35.6 billion takeover of Perrigo Company PLC and it will launch a formal offer soon. A representative from Perrigo could not immediately be reached for comment. The proposed deal—which has been swiftly opposed by Perrigo at every turn—was... More...>>
08/28/20158:03AMPRNUSPerrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction Offer Substantially Undervalues Perrigo, Exposes Shareholders to Risk and Mylan's Weak Business Prospects Value Destructive Transaction Would Be Highly Dilutive to EPS and Perrigo's Growth and P/E Multiple Perrigo Positioned to Create... More...>>
08/28/20157:21AMPRNUSMylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo
Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo Mylan Intends to Launch Formal Offer to Perrigo Shareholders in the Coming Weeks PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today... More...>>
08/25/20152:59PMPRNUSMylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceedings against Two Copaxone® 40 mg/m...
Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceedings against Two Copaxone® 40 mg/mL Dosing Patents PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that... More...>>
08/25/20152:13PMPRNUSMylan Launches Generic Zosyn® Injection
Mylan Launches Generic Zosyn® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the... More...>>
08/25/20151:20PMPRNUSMylan Comments on Misleading Statements Made by Perrigo
Mylan Comments on Misleading Statements Made by Perrigo PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today commented on the misleading statements made by Perrigo Company plc (NYSE: PRGO; TASE) in relation... More...>>
08/21/20153:19PMPRNUSMylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo
Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 21, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 21, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today clarified certain inaccuracies by third parties... More...>>
08/18/201511:31AMPRNUSMylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities
Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today commented on a warning letter issued by the U.S. Food and Drug Administration... More...>>
08/18/20157:30AMPRNUSMylan Confirms First-to-File Patent Challenge Relating to Zytiga®
Mylan Confirms First-to-File Patent Challenge Relating to Zytiga® -Expects to be eligible for 180 days of marketing exclusivity- PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today confirmed that the company... More...>>
08/14/20151:30PMPRNUSPaulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo
Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo PR Newswire NEW YORK, Aug. 14, 2015 NEW YORK, Aug. 14, 2015 /PRNewswire/ -- On behalf of funds that it manages, Paulson & Co. today voted all of its 21.9 million Mylan (NASDAQ: MYL) shares in support of the proposed merger with Perrigo (NYSE:... More...>>
08/14/201511:07AMPRNUSISS Affirms Perrigo's Position That Proposed Mylan Transaction Would Be Value Destructive
ISS Affirms Perrigo's Position That Proposed Mylan Transaction Would Be Value Destructive - "Proposal would incur significant dilution with almost no subsequent leverage to drive an optimal outcome" - "Many uncertainties to the rest of the process and the unusually long period before it is expected to become... More...>>
08/14/20159:18AMPRNUSMylan Responds to ISS Recommendation Regarding Perrigo Transaction
Mylan Responds to ISS Recommendation Regarding Perrigo Transaction Notes Glass Lewis and Egan Jones Both Recommended a Vote For the Perrigo Transaction ISS Repeatedly Acknowledges Solid Business Strategy and Industrial Logic of Perrigo Transaction and Value of Deal to Perrigo Shareholders Mylan Continues to Believe Transaction... More...>>
08/14/20159:00AMDJNProxy Adviser Says Mylan Holders Should Shun Perrigo Deal
Institutional Shareholder Services, an influential shareholder-vote adviser, recommended that Mylan NV investors vote against authorizing the company's $36 billion takeover of Perrigo Co., saying the deal faces too many hurdles. The ISS report, issued Friday to the firm's clients, cited "unreasonable uncertainties," including... More...>>
08/13/20157:00AMPRNUSMylan Lowers Acceptance Condition on Perrigo Offer to Greater than 50%
Mylan Lowers Acceptance Condition on Perrigo Offer to Greater than 50% PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 13, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 13, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it has formally lowered the acceptance condition for its offer to acquire... More...>>
08/12/20153:01PMPRNUSMylan and Disney Team Up to Bring New Resources to Life for Families Managing Potentially Life-Threatening Allergies
Mylan and Disney Team Up to Bring New Resources to Life for Families Managing Potentially Life-Threatening Allergies New website, books and culinary events encourage anaphylaxis awareness and readiness PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015... More...>>
08/12/20152:09PMPRNUSEgan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal
Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Egan-Jones, one of the leading U.S. proxy... More...>>
08/12/20159:04AMPRNUSGlass Lewis Recommends Mylan Shareholders Vote For Perrigo Transaction Proposal
Glass Lewis Recommends Mylan Shareholders Vote For Perrigo Transaction Proposal PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Glass Lewis & Co., one of the leading U.S. proxy advisory... More...>>
08/10/20159:01AMPRNUSMylan Celebrates EpiPen4Schools® Third Anniversary, Program Extension Encourages Anaphylaxis Awareness and Preparedness This...
Mylan Celebrates EpiPen4Schools® Third Anniversary, Program Extension Encourages Anaphylaxis Awareness and Preparedness This Back-to-School Season More than 56,000 schools have participated nationwide PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 10, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 10, 2015... More...>>
08/10/20157:30AMPRNUSMylan Launches Generic Version of Lidoderm® Patch
Mylan Launches Generic Version of Lidoderm® Patch PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 10, 2015 HERTFORDSHIRE, England and PITTSBURGH, Aug. 10, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq myl150902 10:49